AZNCF News and Press, AstraZeneca Plc From 03/14/21

This ETF has performed well in 2020, despite the kind of devastating impact the COVID-19 pandemic had on emerging-market economies like South Africa or Brazil. We anticipate potentially larger macroeconomic discrepancies between the largest and smallest global economies due to the COV...

Starpharma rises on a partnership with Merck on DEP-Antibody Drug Conjugates. AstraZeneca AZD0466 (with Starpharma DEP technology) Phase 1 trial goes global. Viraleze, registered in Europe and positioned as a COVID preventative/early treatment, stable at room temperature and compa...

Pfizer sees $15 billion revenue from the Pfizer/BioNTech COVID vaccine in 2021 and it could completely change Pfizer’s revenue and earnings trajectory. Think about what this will do for BioNTech. The above revenues are for the “pandemic phase.” Pfizer/BioNTech may...

Merger activity decreased last week with four new deals announced. The acquisition of Enable Midstream Partners by Energy Transfer. The acquisition of Tribune Publishing Company by Alden Golden Capital. For further details see: Merger Arbitrage Mondays - Consolidati...

The fund's written options strategy has resulted in a realized loss of approximately $106 million, or roughly 6% of total NAV. ETY has high exposure to the IT sector, which could minimize the relative performance compared to its benchmarks in the case of growth into value stock market...

Apellis Pharmaceuticals is gearing up for potential approval of its PNH drug pegcetacoplan; the PDUFA date has been established for May 14, 2021. Pegcetacoplan achieved superior increase in hemoglobin levels in a head to heady study against Soliris. Upon FDA approval, pegcetacoplan ma...

Merger activity increased last week with five new deals announced. The acquisition of Glu Mobile by Electronic Arts. MKS Instruments and II-VI Incorporated bid for Coherent. For further details see: Merger Arbitrage Mondays - Bidding War For Coherent Continues

AstraZeneca PLC (AZN) Q4 2020 Earnings Conference Call February 11, 2021, 06:45 AM ET Company Participants Pascal Soriot - Executive Director and Chief Executive Officer Dave Fredrickson - Executive Vice President, Oncology Business Unit Ruud Dobber - Executive Vice President, Biopharmaceutic...

The following slide deck was published by AstraZeneca PLC in conjunction with their 2020 Q4 earnings call. For further details see: AstraZeneca PLC 2020 Q4 - Results - Earnings Call Presentation

AstraZeneca (OTCMKTS: AZNCF) , Swedish drugmaker’s, Covid-19 vaccine proved to be as little as 10% effective against South Africa’s new coronavirus variant, according to a study. The country has now suspended the distribution of the shot within its vaccination progra...